Gabapentin
- Generic Name
- Gabapentin
- Brand Names
- Gralise, Neurontin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H17NO2
- CAS Number
- 60142-96-3
- Unique Ingredient Identifier
- 6CW7F3G59X
- Background
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
- Indication
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
- Associated Conditions
- Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
- Associated Therapies
- -
Prevention of Persistent Opioid Use in Mothers
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 78
- Registration Number
- NCT03472521
- Locations
- 🇺🇸
Lucille Packard Children's Hospital, Palo Alto, California, United States
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03423264
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2021-09-08
- Target Recruit Count
- 104
- Registration Number
- NCT03393702
- Locations
- 🇵🇱
Institute for Tuberculosis and Lung Diseases, Pediatric Division, Rabka-Zdrój, Małopolska, Poland
Efficacy of Multimodal Analgesia Following Hip Arthroscopy
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 100
- Registration Number
- NCT03351439
- Locations
- 🇨🇦
Fowler Kennedy Sport Medicine Clinic, London, Ontario, Canada
Gabapentin Regimens and Their Effects on Opioid Consumption
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT03334903
- Locations
- 🇺🇸
Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States
Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT03335436
Gabapentin for Bipolar & Cannabis Use Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 23
- Registration Number
- NCT03334721
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 65
- Registration Number
- NCT03269344
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Masaryk University
- Registration Number
- NCT03255330
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 54
- Registration Number
- NCT03220776
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.